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Abstract
Rapid diagnostic tests are used for the determination of binary qualitative results not
only uniquely in nonhospital-based but also in hospital-based tests.  Principally,  in
developing countries, rapid diagnostic tests are the primary option since tests to be used
in medical laboratories are discarded due to the higher cost. The test’s performance is
evaluated  to  assure  that  the  chance  of  results  to  be  false  is  clinically  acceptable.
Therefore, the diagnostic accuracy of results (diagnostic sensitivity and specificity) is
assessed  to  guarantee  the  safety  of  postclinical  decision.  The  statistical  approach
requires  that  representative  samplings  of  the  populations  of  infected  and healthy
individuals are tested. The area under the receiver-operating characteristic (ROC) curve
is a complementary measurement using the same samplings. It represents the diagnostic
accuracy in a single outcome. When samplings with known diagnostics are unavaila‐
ble, samplings with known outcomes from a comparative test are used to determine the
agreement of results. However, this approach is secondary, due to diagnostic accura‐
cy to be unmeasurable. The seronegative period is another critical measurement that
allows determining an individual biological bias during a period where results of an
infected individual are false-negatives due to seroconversion. The claimed require‐
ments should be defined for diagnostic accuracy and agreement outcomes. A spread‐
sheet  is  used  to  estimate  the  results  considering  the  absolute  value  and  the  95%
confidence interval.
Keywords: clinical decision, point-of-care testing, quality assurance, quality control,
rapid diagnostic test
1. Introduction
Point-of-care testing (POCT) is defined by the International Organization for Standardization
(ISO) as the “testing that is performed near or at the site of the patient with the result leading to
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a possible change in the care of the patient” [1]. Clinical and Laboratory Standards Institute
(CLSI) recognizes this definition and proposes another: “testing performed outside a central
laboratory environment, generally nearer to, or at the site of the patient/client” [2]. Currently,
31% of the global in vitro diagnostics’ (IVD) commercial tests are POCT [3]. The US POCTs
represent close to 45% of the IVD market, followed by Europe and Japan. The global POCT
market is estimated to increase to reach US$ 30 billion by 2020, with a compound annual growth
rate close to 10% [4]. The POCT for the detection of infectious disease agents is 21.9% of the
forecast POCT global market segments in 2016 [5].
Rapid diagnostic test (RDT) is one type of POCT intended to a fast detection of the antigens
or antibodies present in human samples. RDT is a qualitative (or semiquantitative) test, and it
is defined as the test “that detect and/or identify a particular analyte, constituent, or condi‐
tion (note: this term applies to tests that detect whether a particular analyte, constituent, or
condition is present or absent and sometimes assigned a positive degree (i.e., 1+, 2+)” (entry 4
in Ref. [2]). According to the International Vocabulary of Metrology (VIM), generally RDT
result is analogous to nominal quantity (entry 4.26 of Ref. [6]) tests. This quantity is defined as
the “rounded or approximate value of a characterizing amount of a measuring instrument or
measuring system that guides its appropriate use,” for example, positive/negative. Nominal
quantities are sometimes confused with ordinal quantities (entry 1.26 of Ref. [6]), where a
value’s classification is according to a decision value on an ordinal scale, for example, a result
equal or higher than the clinical decision point (“cutoff”) is classified as positive, and if below
—negative. RDTs are usually used as screening tests, namely, in cases where the cost per result
must be lower than that if it is used in the medical laboratory test such as that happens
predominantly in developing countries. They are also used when the need for an outcome is
an emergent such as in an emergency room. RDT should provide accurate, precise, and reliable
test results. Unreliable results have a significant probability to be untrue, affecting the clinical
decision directly. According to the current good laboratory practice, RDT results should not
be final results. However, in developing countries, it is frequently considered an end out‐
come, for what the physician should understand the risk of clinical decisions’ failure due to
false results. Accordingly, the laboratorian should perform a set of quality control tests to
evaluate the accuracy of the RDT results. This is intended to determine and verify that the error
associated to the in vivo results is not clinically significant (allowable error), that is, it does not
affect the clinical decision significantly. When quality control tests are not performed, the
residual risk (entry 2.29 of Ref. [7]) linked to the chance of incorrect clinical decisions due to
abnormal results is unknown. Evidenced-based reported cases [8–11] demonstrate the impact
of bad quality control practices of POCT in the clinical decisions, contributing to a discus‐
sion on the accuracy of POCT results and its association with unsafe clinical decisions [12].
Quality control (entry 3.3.7 of Ref. [13]) is a part of the quality assurance (entry 3.3.6 of Ref.
[13]). It is a set of models designed to monitor the test’s results. Its goal is to assure that the
outcomes (true result + error) are not significantly distant from the in vivo results. Test
evaluation should be performed determining the diagnostic accuracy of the assay focused on
diagnostic sensitivity and specificity. The area under the receiver-operating characteristic
curve (AUC) is a complementary measurement that permits the calculus of diagnostic
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uncertainty in a single outcome. Both determinations are statistical measures of the perform‐
ance of a binary result (positive or negative). However, to use these applications, there must
be available samplings from infected individuals D1 and healthy individuals D0. When the
comparator is other than diagnostic, it should be determined as the agreement of results. The
seronegative window period is another required measurement in an RDT evaluation. This
model evaluates the seronegative period in an infected individual, during which the posi‐
tive results are biologically biased, that is, they are systematically false negative.
Associated with all the presented approaches is the absence of metrological traceability of the
results due to the unavailability of certified reference materials or reference methods (entry
2.41 of Ref. [6]). Therefore, RDTs are classified as untraceable tests. For a thorough discus‐
sion of metrological traceability in medical laboratories’ tests, further information can be found
elsewhere [14].
This chapter reviews and discusses models of diagnostic accuracy, agreement of results, and
seronegative window period applied to the RDTs’ evaluation. It is presented as an example a
case study considering the worst scenario in a blood establishment: the use of a small number
of samples where the evaluation cost must be minimum. Despite this example contributes to
a less reliable estimation, its role in the consistency of the assessment remains significant.
Differently from the tests’ evaluation, the determination of measurement uncertainty (entry
2.26 of Ref. [3]) is not systematically applied to RDTs. However, it is considered in the estimates,
considering risk-based thinking principles [15–17]. A flowchart summarizes and hierarchiz‐
es the alternatives in the selection of evaluation models. Internal quality control (entry 3.3 of
Ref. [18]) and external quality assessment/proficiency testing (entry 5.1 of Ref. [19]) models are
out of the chapter’s scope. Ethical issues are also out of the scope. A report on legal and ethical
questions of RDT is found elsewhere [20].
The theoretical principles were applied using standard spreadsheet software (Microsoft®
Excel®), freely available at DOI: 10.13140/RG.2.1.1123.1766.
2. Comparison of results
2.1. Diagnostic accuracy I: 2 × 2 contingency tables
2.1.1. General concept
Diagnostic accuracy models are used to determine the RDT performance using diagnostic
accuracy criteria (i.e., disease and nondisease), adopting a Bayesian probability framework.
This is a concept of probability where the hypothesis of a certain condition (e.g., infected and
healthy) is measured in a sampling. For this measurement, two samplings are required: one
featuring infected individuals and another featuring healthy individuals. Both samples should
be carefully selected to minimize the probability of sources of biological bias considerably,
principally “spectrum bias.” Pepe [21] defined this type of bias as the “bias between estimat‐
ed test performance and true test performance when the sample used for evaluating an assay
does not properly represent the entire disease spectrum over the target (intended-use)
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population” (entry 4.2 of Ref. [21]). The evaluator of test report recognizes there is always an
estimated risk of biased results, mainly from samples of individuals in the seroconversion
window period (see Section 2.4.), where the concentration of antibodies or antigens is below
the RDT “cutoff.” Figure 1 illustrates the case when results of infected and healthy individu‐
als’ samples are misclassified, expressing false binary results. In this example, the results are
incorrectly equal, higher or lower than the “cutoff.” RDTs use a visual “cutoff” point, instead
of a numerical value on an ordinal scale such as that used in diagnostic immunoassays.
Figure 1. Classification of false results (biased results).
The performance of results is measured using diagnostic sensitivity and diagnostic specifici‐
ty essentially. These terms are also recognized as clinical sensitivity, sensitivity or true positive
rate and clinical specificity, specificity or true negative rate, respectively.
2.1.2. Diagnostic sensitivity
Diagnostic sensitivity Se [%] measures the percentage of true positive results in an infected
individuals’ sampling, that is, the true-positive results rate in percentage (entry 5.3 of Ref. [22]).
It is determined by the mathematical model (entry 10.1.1 of Ref. [22]):
[%] 100TPSe TP FN= ×+ (1)
where TP is the total of true-positive results, and FN is the total of false-negative results. The
RDT should have a high diagnostic sensitivity to assure a nonsignificant residual risk of the
erroneous clinical decision. High sensitivity suggests a high chance of true-positive results.
The risk of producing false-positive or false-negative results is readily identified by the
statistician to the statistical hypothesis testing as β-error or type II error or α-error or type I
error, respectively. Diagnostic sensitivity is equal to 1 − FN = 1 – β-error, for what it is similar
to the concept of the statistical power of a binary hypothesis test (entry 2.1 of Ref. [23]),
representing the capability of an assay to detect a real effect. Detailed information about
statistical hypothesis tests and diagnostic accuracy tests is found elsewhere [21, 23].
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The false-negative rate FN [%] determines the percentage of false-negative results in the
infected individuals’ sampling. It is referred to as “diagnostic uncertainty,” since it gives a
primary sense of the risk of uncertain results [24]. Consequently, “diagnostic uncertainty” of
a RDT is defined as “the risk of false results.” This concept is analogous to the “measure‐
ment uncertainty” intended to be applied to numerical quantity results (entry 1.20 of Ref. [6]).
The determination of measurement uncertainty is demonstrated uniquely in ordinal diagnos‐
tic tests [25, 26]. In such cases, this terminology could be adapted to “measurement uncertain‐
ty of binary results.” Measurement uncertainty in an RDTs’ results is associated principally
with the effect of between-users reading in measures of imprecision.
The false-negative rate is determined by the mathematical model (entry 10.1.4 of Ref. [22]):
  [%] 100FNFN TP FN= ×+ (2)
2.1.3. Diagnostic specificity
Diagnostic specificity Sp [%] measures the percentage of true-negative results in a healthy
individuals’ sampling, that is, the true-negative results rate in percentage (entry 5.3 of Ref.
[22]). It is determined by the mathematical model (entry 10.1.1 of Ref. [22]):
[%] 100TNSp FP TN= ×+ (3)
where TN is the total of true-negative results and FP is the total of false-positive results. The
false-positive rate FP [%] determines the percentage of false-positive results in the healthy
individuals’ sampling. In the same manner as the FN [%], it could be referred as “diagnostic
uncertainty” [24]. It is determined by the mathematical model (entry 10.1.4 of Ref. [22]):
  [%] 100FPFP FP FN= ×+ (4)
The true and false results can be expressed in a 2 × 2 contingency table as displayed in Table 1.
Candidate test results Diagnostic accuracy criteria Total
Positive (disease, D = 1) Negative (nondisease, D = 0)
Positive (y = 1) True-positive results (TP) False-positive results (FP) α-error TP + FP
Negative (y = 0) False-negative results (FN) β-error True-negative results (TN) FN + TN
Total TP + FN FP + TN N
Table 1. 2 × 2 contingency table for diagnostic accuracy.
Evaluation of Rapid Diagnostic Test Performance
http://dx.doi.org/10.5772/64179
143
Predominantly, in rare tests, it could be difficult to have samples with an accurate diagnostic,
for what comparative test results should be used when the diagnosis is unknown (see
Section 2.3).
2.1.4. Inference of the results for the 95% confidence interval
The rates are applied uniquely to the sampling. They cannot be inferred to the populations. A
diagnostic sensitivity equal to 100% is interpreted as a 100% probability of a result of an infected
individual from the infected individuals’ sampling to be a true positive. It cannot be under‐
stood as the likelihood of a person from the population of infected subjects to have a true-
positive result.
Nonetheless, an inference could be used to the people of the same characteristics of sam‐
pling. Commonly, a confidence interval is used to infer to 95% of the population (95% CI),
considering a risk of untrueness throughout α or β-error. To determine the 95% score confi‐
dence limits, the low limit and high limit are determined. Considering the level of trust equal
to 1 – α-error, the significance level is equal to 5%. In practice, it can be statistically consid‐
ered that it is 95% confident about the inclusion of true results in the interval or the error margin
of 5% false results attributed to that statement.
For the diagnostic sensitivity, the low-limit interval LLse and high-limit interval LLse are
computed from the mathematical models (entry 10.1.3 of Ref. [22]):
1, 2,
3,
[%] 100se sese
se
Q QLL Q
-= × (5)
1, 2,
3,
[%] 100se sese
se
Q QHL Q
+= × (6)
where Q1,se = 2 · TP + 1.962, Q2,se =1.96⋅ 1.962 + 4⋅TP ⋅FN / (TP + FN ), and Q3,se = 2 · (TP + FN +
1.962).
Low and high limits for the test’s diagnostic specificity are computed, respectively, by (entry
10.1.3 of Ref. [22])
1, 2,
3,
[%] 100sp spsp
sp
Q QLL Q
-= × (7)
1, 2,
3,
[%] 100sp spsp
sp
Q QHL Q
-= × (8)
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where Q1,sp = 2 · TN + 1.962; Q2,se =1.96⋅ 1.962 + 4⋅FP ⋅TN / (FP + TN ), and Q3,sp =2 · (FP + TN +
1.962).
2.1.5. Overall accuracy
Efficiency is an overall estimation of the accuracy in the samplings expressing the percent‐
age of true results in the total of results (entry 4 of Ref. [27]). It is determined by the mathe‐
matical model (entry 9.1 of Ref. [27]):
[%] 100TP TNEff N
+= × (9)
2.1.6. Predictive values
The prediction value of negative results, positive results, or both in a sampling or popula‐
tion has interested the clinical field. Physicians may wish to know the probability of true result
to be associated with the presence or absence of a disease, and these can be provided easily.
Predictive value of a positive result or positive predictive value PPV [%] measures the
percentage of infected individuals in the positive results sampling (entry 5.3 of Ref. [22]). It is
determined by the mathematical model (entry 10.3.1 of Ref. [22]):
[%] 100TPPPV TP FP= ×+ (10)
Predictive value of a negative result or negative predictive value NPV [%] measures the
percentage of healthy individuals in the negative results sampling (entry 5.3 of Ref. [22]). It is
determined by the mathematical model (entry 10.3.1 of Ref. [22]):
[%] 100TNNPV TN FN= ×+ (11)
2.1.7. Prevalence of infected individuals’ sampling
Prevalence is not an indicator of performance, but an indicator of the frequency of infected
individuals’ samples in the total number of subjects. Prevalence of infected individuals Pr [%]
measures the percentage of infected persons in the total of tested subjects (entry 5.3 of Ref. [22]).
It is determined by the mathematical model (entry 10.3.1 of Ref. [22]):
[%] 100TP FNPr N
+= × (12)
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2.1.8. Reproducibility conditions of the study
The sample’s measurement should occur in reproducibility conditions, to assure the study
evaluates the major error components of the test. For example, if the RDT is to be used by more
than one user, it should be tested by all, or if unfeasible, by a representative sampling. Usually,
it is recommended the evaluation take place in a period during 10–20 days (entry 9.3 of Ref.
[22]). This period is understood as the time when all significant causes of error are expected
to happen. However, batch-to-batch variation is commonly omitted, which requires that each
batch should be evaluated independently. Sometimes, the evaluations of different batches are
done by the inference of one batch’s evaluation, which is statistically incorrect since a single
batch is not representative of a reagent’s manufacturer production.
2.1.9. Interference of results
The samples should be verified taking into account the causes of pre-analytical interference to
minimize the risk of false results, biasing diagnostic sensitivity and specificity results. The
contribution to false results of anticoagulant, bilirubin, erythrocytes, hemoglobin, dialysis [28],
disease effects [29], drugs’ effects [30], herbs, and natural products is recognized [31]. The
laboratorian could identify the documented interference in published literature or the
manufacturer’s paper inserted in the reagent kit.
2.1.10. Re-evaluation
The RDT re-evaluation should occur principally when significant epidemiological changes
happen; however, other changes require a re-evaluation such as the alteration of the users or
even a change in the reagent batch.
2.2. Diagnostic accuracy II: area under the receiver operating characteristic curve
2.2.1. Receiver operating characteristic curve
ROC curve could be defined as “a graphical description of test performance representing the
relationship between the diagnostic sensitivity and the false-positive rate” (entry 4.2 of Ref.
[32]). Figure 2 shows three ROC curves. ROC A assures 100% true results using infinite number
of determinations from samplings of infected and healthy individuals, which is an unrealis‐
tic case; ROC B assumes a realistic situation where a negligible probability of false result
happens; and ROC C assures 100% true false results, which is an unrealistic example. A curve
following closer to the left-hand border and then the top border represents accurate test’s
results. ROC is purely a graphical plot exhibiting the performance of an assay as the “cutoff”
differs. Accordingly, its application to the RDT user is hard to apply, since there is no
numerical “cutoff” but uniquely a visual “cutoff,” which cannot be expressed as a numerical
quantity by the user. A semiquantitative classification such as a positive degree is not applied
usually to these tests.
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Figure 2. Three hypothetical ROC curves.
2.2.2. Area under the receiver operating characteristic curve
The area under the receiver operating characteristic curve (AUC) determines the ability of a
test to classify accurately or discriminate samples. It ranges from 0.5 to 1, signifying respec‐
tively, binary results randomly assigned to a sample and a perfect test discrimination. It could
be measured using parametric or nonparametric models [24], such as the D’Agostino-Pearson
normality test AUCp [33] and the Mann-Whitney U statistical test AUCnp [34], corresponding‐
ly. Both models could be computed using the data previously requested in Section 2.1.:
( ) ( )pAUC FPF c TPF c= × (13)
where FPF(c) is the false-positive rate for a defined “cutoff” value c and TPF(c) is the true-
positive rate for the same “cutoff” [35].
1 0/npAUC U n n= × (14)
where U = (n1 · n0 + n0 · (n0 + 1))/(2 − R), where R is the rank sum of squares; n1 is the number
of negative specimens; and n0 is the number of positive samples [34].
The difference between one and the AUC could also be referred as “diagnostic uncertainty” of
estimation.
Test discrimination could be classified according to the AUC, using the following ratings [36]:
– if AUC ∈ [0.50, 0.70] the distinction is poor;
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– if AUC ∈ [0.70, 0.80] the distinction is acceptable;
– if AUC ∈ [0.80, 0.90] the distinction is excellent;
– and if AUC ∈ [0.90, 1.00] the distinction is outstanding.
The accuracy of AUC is restricted by the number of true and false results. It gives an overall
evaluation of RDT performance, complementing diagnostic sensitivity and specificity
estimates [24]. As in Section 2.1.4, a confidence interval should be related to the AUC to
evaluate if changes in AUC between classifiers are statistically significant in the inferred range.
The report evaluator could erroneously infer about the capacity of an RDT to discriminate the
results if the absolute values are considered uniquely. The 95% CI could be computed
according to the model
1  .96 · SE[AUC]±AUC (15)
Where SE[AUC] is the standard error determination of the AUC which is computed by
Var[TP]/n1+Var[FP]/n2 where Var[TP] is the variance of true positive results,n1is the number
of true positive results, Var[FP] is the variance of false positive results, and n2 is the number
of false positive results [37]. Despite apparently it has the advantage of the results to be centered
on the absolute value, it was not recommended by Newcombe [38], claiming the feature of
symmetry leads to an uncorrected calculus due to “overshoot” and “degeneracy.” New‐
combe suggested the Clopper-Pearson model for calculating exact binomial confidence
intervals, used to the 95% CI determination, eliminating the incidence of both defects. The
model contemplates the interval [AUCLL, AUCHL] with AUCLL ≤ p ≤ AUCHL, such that for all θ
in the interval:
: / 2        ,     ; andLL r j r j n jif AUC p kp p aq < £ ³£ £ +S (16)
:0 / 2          ,        HL r j j n j rif p AUC kp p kp aq £ < ³£ £ +S + (17)
where j = 0, 1,…, n, R representing the random variable of which r is the realization, and k = 1
[39].
The significance level is equal to 5%, and it is another analogy to “diagnostic uncertainty”
(see Section 2.1.4).
Since the AUC depends primarily on the number of true and false results, it is determined in
RDT, considering the used “cutoff” exclusively.
2.2.3. Reproducibility, interferences, and re-evaluation
The reproducibility conditions, the interferences, and the re-evaluation are considered as seen
in Sections 2.1.8, 2.1.9, and 2.1.10, respectively.
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2.3. Agreement of binary results when comparator is other than diagnostic accuracy criteria
2.3.1. General concept
The principles used in Section 2.1 to compute the rates are not applicable to the determina‐
tion of agreement between results of a candidate RDT and a comparative test. Despite the
mathematical models being similar, the diagnostic accuracy is unmeasurable since the
individuals’ diagnostic is unidentified. It classifies merely the concordance of results. In this
model, the diagnostic is replaced by the outcome of a comparative test different from a
“gold standard” test [22]. The comparative test should have an acceptable diagnostic accura‐
cy to minimize bias. When there is only available a comparative test without acknowledged
diagnostic accuracy, the risk of bias effect in concordance is major, which could signify the
agreements’ results are unrealistic when compared to diagnostic accuracy. For example, this
case happens if the comparative test’s diagnostic accuracy is lower than that in the candi‐
date RDT. In this condition, a nonconcordance could be erroneously interpreted. The evalua‐
tion is also erroneous when the agreement concept is misinterpreted as diagnostic accuracy.
Table 2 summarizes the agreement of binary results and the α and β errors.
Candidate test results Comparative test Total
Positive (x = 1) Negative (x = 0)
Positive (y = 1) Positive agreement (a) Negative disagreement (b), α-error a + b
Negative (y = 0) Positive disagreement (c), β-error Negative agreement (d) c + d
Total a + c b + d n
Table 2. 2 × 2 contingency table for test results agreement.
2.3.2. Agreement of overall results
The percentage of positive and negative results agreement is designated “overall percent
agreement” OPA [%], and it is computed by (entry 10.2.1 of Ref. 22])
[%] 100a dOPA n
+= × (18)
where a is the total of candidate test’s positive results among the positive results of the
comparative test, d is the total of candidate test’s negative outcomes among the negative results
in the comparative test, and n is the total number of samples.
2.3.3. Agreement of positive results
The percentage of positive results agreement is designated “positive percent agreement” PPA
[%], and it is computed by (entry 10.2.1 of Ref. [22])
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[%] 100aPPA a c= ×+ (19)
2.3.4. Agreement of negative results
The percentage of negative results agreement is designated “negative percent agreement” NPA
[%], and it is computed by (entry 10.2.1 of Ref. [22])
[%] 100dNPA b d= ×+ (20)
2.3.5. Inference of the results for the 95% confidence interval
Such as in the diagnostic accuracy (see Section 2.1.4) to infer an estimation to the population,
a 95% confidence interval is used. Accordingly, the low and high limits for the test’s overall
percent agreement are computed respectively by (entry 10.2.2 of Ref. [22])
1, 2,
3,
[%] 100OPA OPAOPA
OPA
Q QLL Q
-= × (21)
1, 2,
3,
[%] 100OPA OPAOPA
OPA
Q QHL Q
+= × (22)
where Q1,OPA = 2 · (a + d) + 1.962, Q2,OPA =1.96⋅ 1.962 + 4⋅ (a + d )⋅ (b + c) / n and Q3,OPA = 2 · (n + 1.962).
Low and high limits for the test’s positive percent agreement are computed respectively by
(entry 10.2.2 of Ref. [22])
1, 2,
3,
[%] 100PPA PPAPPA
PPA
Q QLL Q
-= × (23)
1, 2,
3,
[%] 100PPA PPAPPA
PPA
Q QHL Q
+= × (24)
where Q1,PPA = 2 · a + 1.962, Q2,PPA =1.96⋅ 1.962 + 4⋅a ⋅c / (a + c), and Q3,PPA = 2 · (a + c + 1.962).
Low and high limits for the test’s negative percent agreement are computed, respectively, by
(entry 10.2.2 of Ref. [22])
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1, 2,
3,
[%] 100NPA NPANPA
NPA
Q QLL Q
-= × (25)
1, 2,
3,
[%] 100NPA NPANPA
NPA
Q QHL Q
-= × (26)
where Q1,NPA = 2 · d + 1.962, Q2,NPA =1.96⋅ 1.962 + 4⋅b ⋅d / (b + d ), and Q3,NPA = 2 · (b + d + 1.962)
(note: a, b, c, and d are analogous to the number of “true positives,” “false positives,” “false
negatives,” and “true negatives” results of diagnostic accuracy).
The significance level is equal to 5%, and it is another time analogous to “diagnostic uncer‐
tainty.” The claimed confidence interval should take into consideration the same limitations
associated with the selection of intervals also discussed in Section 2.1.4.
2.3.6. Reproducibility and interferences
The reproducibility conditions and the interferences are treated as seen in Sections 2.1.8 and
2.1.9, respectively.
2.3.7. Re-evaluation
The RDT re-evaluation should take place mainly when significant epidemiological changes
happen, and the comparative test is re-evaluated. As seen in Section 2.1.10, the variations in
the batch of the reagent also involve re-evaluation study.
2.4. Seroconversion window period
2.4.1. General concept
The seroconversion window period is also recognized as the “seronegative period” or the
“seroconversion sensitivity” [40]. Seroconversion period is defined as “the window period for
a test designed to detect a specific disease (particularly an infectious disease) is the time
between first infection and when the test can reliably detect that infection” [41]. The window
period is equal to the number of days starting on the day of infection (day zero) to the day of
the first positive result, that is, the time taken for seroconversion. Pereira et al. [42] proposed
an alternative definition considering a trinary classification (i.e., positive/indeterminate/
negative), which is uniquely applicable to tests with an ordinal scale of results.
2.4.2. Seronegative period
The evaluation of a seroconversion panel allows a primary determination of the most critical
source of bias (biological bias), that is, the seronegative period. It is the major component of
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the risk of the incorrect clinical decision [39]. The window period is also a diagnostic accura‐
cy test despite not commonly classified as such to distinguish from Bayesian models (see
Section 2.1).
The window period performance differs according to the type and the generation of the test.
It depends also on the seroconversion panel used, which represents a unique infected
individual and cannot be inferred to all the people with risk behaviors. Consequently, this
period cannot be related to all the seronegative persons. It should not be misunderstood as the
window period of a test, which is unknown. A benchmarking study should consider the
shortest period in a rank of tests for comparison, usually coming with inserted literature in
seroconversion panel.
For an in-depth discussion of seroconversion window period, further information can be found
elsewhere [43].
2.4.3. Re-evaluation
The re-evaluation should only occur when a new panel with a shorter period is available. The
laboratorian should consult the updated list of obtainable panels in the websites of manufac‐
turers or the published literature.
3. Results and discussion
3.1. A case study
A practical example of the use of RDT results is in the evaluation of human blood compo‐
nents in a blood establishment (blood bank). In this case, the selection of the infected individ‐
uals should take into consideration the epidemiological prevalence not only of the tested agent
but also types, subtypes, and other variants of significant epidemiological prevalence in the
geographic area of the candidates to blood donors. If the sampling does not feature all the
epidemiological significant variants, the diagnostic sensitivity is biased, and the results of the
new variants are inaccurate. Otherwise, the selection of healthy individuals’ sampling should
include uniquely subjects recognized as noninfected. The regular blood donors’ population is
the best source for sampling of healthy subjects, since they are clinical and laboratory screened
during a long term.
3.2. The rapid diagnostic test
To exemplify the models is used a single commercial RDT to detect antihuman immunodefi‐
ciency virus types 1 (HIV-1) and 2 (HIV-2) antibodies in human serum, plasma, venous blood,
and capillary blood. Since it is to be used uniquely with serum, the evaluation occurs using
serum specimens. The recombinant antigens (HIV-1 gp120, gp41, and HIV-2 gp36) conjugat‐
ed to colloidal gold are adsorbed on a base of a strip of nitrocellulose membrane. There are
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two test zones: (1) test zone, where HIV-1 and HIV-2 antigens are immobilized, and (2) control
zone, where anti-HIV antibodies are immobilized. For internal quality control of the test is
used a control zone. Interpret results as follows: there is no red strip in the test zone when the
antibodies anti-HIV-1 or anti-HIV-2 are immeasurable, and there is a red strip in the control
zone due to the migration of the antigen-conjugate gold (negative result). If the antibodies anti-
HIV-1 or anti-HIV-2 are measurable, both zones have a red strip (positive result). Whenever
the control zone does not have a red strip, the results do not have a binary classification
(unclassified results). Repetitive positive must be tested using a confirmatory test, such as
Western Blot, for antibodies.
3.3. Diagnostic accuracy I: 2 × 2 contingency tables
The evaluation contemplates a worst case considering:
– The laboratorians are trained successfully;
– The assessment is performed in a short period in reproducibility condition;
– The number of samples of infected individuals and healthy individuals is minor to assure
a low cost of the assessment and to be feasible for a short period;
– The intended use of the RDT results is the screening of individuals with risk behavior to
HIV infection.
Considering the major problem to a clinical decision to be false-negative outcomes, a larger
number of infected individuals’ samples is selected (n = 10), when compared to the number of
healthy individuals (n = 5). The performance focuses on diagnostic sensitivity instead of
diagnostic specificity. The samples are from diagnosed patients infected with HIV-1 (n = 9)
and HIV-2 (n = 1), with repeated positive results to a fourth generation chemiluminescence
immunoassay, Western Blot, and nucleic acid test (reverse transcription-polymerase chain
reaction). Healthy subjects are regular blood donors tested in last three blood donations, with
successive negative results to a fourth generation chemiluminescence immunoassay. The HIV
group of the tested samples is not classified.
The claimed performance is determined according to the manufacturer’s literature and the
number of samples. When a 95% CI minimum requirement is claimed, the number of samples
must be considered, since it is a restriction of the claim. Requested performance for absolute
results is equal to 100% to diagnostic sensitivity and 90% to diagnostic specificity. The best
diagnostic sensitivity’s low limit is equal to 72.2%, and diagnostic specificity’s low limit is equal
to 56.6%, which is useless for the evaluation. In this case, the 95% CI is considered only to
diagnostic sensitivity, since the minor number of healthy individuals’ samples does not assure
a reliable estimate. The lower limit of 95% CI of the claimed diagnostic sensitivity is 65%.
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Samples [n] [%]
D1 D0 Se FNR Sp FPR Eff PPV NPV Pr
Absolute 10 5 100 0 100 0 100 100 100 66.7
95% CI – – 72.2–100 – 56.6–100 – – – – –
Table 3. Number of samples and diagnostic accuracy of binary results.
Table 3 shows the performance rates to the candidate RDT, demonstrating that the require‐
ments have been achieved with an overall accuracy of the test equal to 100%. Figure 3 displays
the true and false results in a three-dimensional data chart. The diameters of the disks are
proportional to the number of outcomes. Despite the prevalence rates are unusable to the test
evaluation, they could be useful to support the clinical decisions by the physician.
Figure 3. Bubble chart for the diagnostic uncertainty outcomes: true-positive (TP), false-negative (FN), false-positive
(FP), and true-negative (TN) results.
It can be described that all samples of infected individuals and healthy individuals reported
true results, and can be statistically considered that it is 95% confident about the inclusion of
true-positive results in the interval or the error margin of 5% false-negative results attribut‐
ed to that statement. The 95% CI can be interpreted as the diagnostic accuracy range.
The predictive value of positive and negative results is equal. This is interpreted as the
samplings’ results are accurately associated to the diagnostic.
3.4. Diagnostic accuracy II: receiver operating characteristic curve
The same data is used to determine the AUC as in the previous model. The AUC is comput‐
ed using the Clopper-Pearson nonparametric method described above, since the hypothesis
of the normal distribution of test results could not be tested. Claimed absolute value is 1.00
and the claimed 95% CI is [0.75, 1.00].
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The AUC absolute value is 1.00, ranking the RDT as an “outstanding discrimination” test, with
a 95% CI equal to [0.78, 1.00], whereby the RDT’s AUC is accepted. It can be considered
statistically that it is 95% confident about the inclusion of true results in the interval or the error
margin of 5% false results attributed to that statement. Such as in Section 2.1.4., the 95% CI can
be understood as the diagnostic accuracy interval. As it was already discussed, the AUC
interpretation considers that the low limit is influenced by the number of samples tested. A
minor number of samples decreases the statistical power of the evaluation, making its use
unreliable.
These calculi are also useful for the definition of “cutoff” point in an RDT in the research and
development phase. The “cutoff” is selected considering mainly its impact on the diagnostic
sensitivity and specificity according to results’ intended use, that could be interpreted as the
adequation of the diagnostic sensitivity and specificity according to its role in the clinical
decision. The measurements needed to plot the ROC curve are essential for manufacturers of
in vitro diagnostics medical devices to determine the “cutoff” value for a test under develop‐
ment. This is also appropriate such as for medical laboratory “in house” and “nonwaived”
modified tests (entry 42 CFR Subparts H, J, K and M of Ref. [44]), where the “cutoff” must be
identified. The AUC single value is applicable only to the samplings of infected and healthy
individuals, and it cannot be related to the population groups. For example, the “cutoff” point
as a result of AUC = 1.00 divides perfectly the two groups, but it is unknown if it divides the
two groups in the population. Then, the AUC 95% CI is determined since it is an inference to
the population characterized in the same manner as the tested sampling. When the popula‐
tion has unlike characteristics than the sampling, the 95% CI is biased. The AUC utility, when
applied to RDT evaluation in practice, is limited to represent the diagnostic test’s accuracy in
a single value, complementing diagnostic sensitivity and specificity results.
3.5. Agreement of binary results when comparator is other than diagnostic accuracy
criteria
The same samplings as that in the previous models are used. They are also tested in a
comparator test; in this example, a second RDT. Claimed requirements determine rates to be
equal to 100% to the overall, positive, and negative agreements. The 95% score low confi‐
dence limit is claimed to be equal or higher than 70% to the overall and positive agreements.
Such as in the 95% CI of diagnostic specificity, the confidence interval is not considered to the
negative agreement. Table 4 displays the estimates of results’ agreement, showing that only
the PPA result is achieved to the absolute and confidence interval. It can be statistically
considered that it is 95% confident about the inclusion of agreements in the interval or the error
margin of 5% disagreements attributed to that statement. In this case, the overall and nega‐
tive agreements results were influenced by one false-negative result of the comparator test.
This is an example of a major inaccuracy (bias) due to the use of a comparator with a weak
performance (poor diagnostic specificity) when compared to candidate test. This evaluation
approach should be only used exceptionally when the diagnosis is unspecified. The evalua‐
tor should use further studies to verify if the inaccurate results are due to the candidate’s or
comparator’s test performance, to reduce the risk of erroneous conclusions.
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Samples [n]
Positive Negative OPA [%] PPA [%] NPA [%]
Absolute 10 5 93.3 100 83.3
95% CI – – 70.2–98.8 70.1–100 43.6–97.0
Table 4. Number of samples and agreement of binary results.
3.6. Seroconversion window period
The Window period estimate is performed with a seropositive commercial panel. The panel
contains six undiluted and unpreserved plasma samples of an infected 19-year-old male. The
manufacturer does not feature any RDT result in the inserted paper. Figure 4 shows that 12
days after the first bleed, the RDT can detect the presence of HIV-1 antibodies reliably. Panel
manufacturer inserted paper demonstrates that HIV RNA (copies/mL) is detected on the first
day of bleed in one test in a series of two. Positive results are determined on the fifth day in
three fourth generation immunoassays (detecting HIV-1 and HIV-2 antibodies, and HIV-1 p24
antigen) in a series of six tests. In a series of five antibody immunoassays, all have positive
results after the 12th day. Thus, the RDT window period is equivalent to the tests to antibod‐
ies in this panel. As predictable, the window period was shorter in immunoassays also
detecting HIV-1 p24 antigen and even shorter in nucleic acid tests. Such happens with any
other test; a confirmatory scheme should be used to establish positive final results in RDT.
Figure 4. Results over time from six samples of a seroconversion commercial panel from a plasma donor who serocon‐
verted over the course of their donation history.
3.7. Recommended flowchart
The selection and practical application of the evaluation models are summarized in a flow‐
chart displayed in Figure 5.
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Figure 5. Flowchart to the selection of models to evaluate a RDT.
4. Conclusion
Summarizing, the diagnostic accuracy of RDT characterizes the level of confidence of binary
results to be accurate (true) and the significance standards of a confidence interval. The
determination of agreement of results is usually not a reliable estimate, for what its estima‐
tion should occur only when there is no possible to test samples with known diagnostic. The
AUC is merely complementary to the diagnostic sensitivity and specificity evaluations. The
seronegative window period is determined to evaluate an approximate period where false-
negative results occur due to the antibodies’ concentration being unmeasurable. This is
expected in populations with a high epidemiological prevalence of tested agent. Such as in any
other test, results have a chance to be untrue, whereby the physician should consider the
predictive value of results during the clinical decisions based on the reported results.
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